EcoDrugPlus

Mitogen-Activated Protein Kinase 1

Ensembl ID : ENSTBEG00000008978
Gene Symbol: MAPK1
1 Cross references
213 Possible Orthologues:

Mitogen-Activated Protein Kinase 10

Ensembl ID : ENSTBEG00000011507
Gene Symbol: MAPK10
1 Cross references
147 Possible Orthologues:

Mitogen-Activated Protein Kinase 14

Ensembl ID : ENSTBEG00000005679
Gene Symbol: MAPK14
1 Cross references
281 Possible Orthologues:

Mitogen-Activated Protein Kinase 8

Ensembl ID : ENSTBEG00000017351
Gene Symbol: MAPK8
1 Cross references
294 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase 1

Ensembl ID : ENSTBEG00000014266
Gene Symbol: MAP2K1
1 Cross references
209 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 1

Ensembl ID : ENSTBEG00000012939
Gene Symbol: MAP3K1
1 Cross references
160 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 12

Ensembl ID : ENSTBEG00000015902
Gene Symbol: MAP3K12
1 Cross references
254 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 13

Ensembl ID : ENSTBEG00000003537
Gene Symbol: MAP3K13
1 Cross references
198 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 5

Ensembl ID : ENSTBEG00000009318
Gene Symbol: MAP3K5
1 Cross references
203 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 8

Ensembl ID : ENSTBEG00000007188
Gene Symbol: MAP3K8
1 Cross references
198 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 9

Ensembl ID : ENSTBEG00000002437
Gene Symbol: MAP3K9
1 Cross references
194 Possible Orthologues:

Monoamine Oxidase A

Ensembl ID : ENSTBEG00000006979
Gene Symbol: MAOA
1 Cross references
147 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).